Tira Chaicha-Brom, MD
Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1548434756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,347, 3.7 times the $360 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TX, where the typical reported total is $2,974.
Across 186 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$525
- Novo Nordisk$463
- Abbott$390
- Lilly USA, LLC$342
- BETA Bionics, Inc.$268
- Dexcom, Inc.$226
- plus $2K from 34 others
Across 2,393 payments — averaging $735.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1.2M
- Eli Lilly$422K
- Pfizer$159K
- Sanofi US Services Inc.$1K
What the payments were for
- Consulting fees$1754%
- Food & beverage$3,59290%
- Education$1323%
- Gifts$772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 20 | $525 |
| Novo Nordisk | 27 | $463 |
| Abbott | 21 | $390 |
| Lilly USA, LLC | 17 | $342 |
| BETA Bionics, Inc. | 5 | $268 |
| Dexcom, Inc. | 10 | $226 |
| Insulet Corporation | 8 | $149 |
| Medtronic(2 entities) | 9 | $149 |
| Corcept Therapeutics | 7 | $133 |
| Mannkind Corporation | 3 | $103 |
| Bayer | 5 | $98 |
| Novartis | 4 | $86 |
| Antares Pharma, Inc. | 4 | $75 |
| AbbVie | 4 | $68 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Cequr Corporation | 2 | $59 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Tandem Diabetes Care, Inc. | 3 | $52 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Boehringer Ingelheim | 2 | $49 |
| Ascensia Diabetes Care US Inc. | 2 | $47 |
| AstraZeneca | 2 | $46 |
| Alvogen Inc | 2 | $40 |
| GRT US Holding, Inc. | 2 | $39 |
| Radius Health, Inc. | 2 | $34 |
| Nevro Corp. | 1 | $34 |
| Soleno Therapeutics, Inc. | 1 | $32 |
| Acella Pharmaceuticals, LLC | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Pfizer | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $22 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Intuity Medical Inc | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$312
- Prolia$175
How this compares
$3,976 in reported general payments places this provider in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 341 | $480,328 |
| OzempicSemaglutide | 291 | $352,976 |
| TrulicityDulaglutide | 121 | $179,526 |
| JardianceEmpagliflozin | 119 | $151,880 |
| Teriparatide | 37 | $132,761 |
| TymlosAbaloparatide | 36 | $107,841 |
| FarxigaDapagliflozin Propanediol | 98 | $95,454 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 88 | $91,470 |
| Tresiba Flextouch U-100Insulin Degludec | 110 | $84,392 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 11 | $73,853 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $66,116 |
| Xigduo XrDapaglifloz Propaned/Metformin | 55 | $62,635 |
| RybelsusSemaglutide | 23 | $47,336 |
| ForteoTeriparatide | 11 | $45,026 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $43,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $342 | $709,741492 claims |
| Novo NordiskOzempic, Rybelsus | $463 | $400,312314 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $49 | $243,350207 claims |
| Alvogen IncTeriparatide | $40 | $132,76137 claims |
| Radius Health, Inc.Tymlos | $34 | $107,84136 claims |
| AstraZenecaFarxiga | $46 | $95,45498 claims |
| NovartisSandostatin Lar Depot | $86 | $73,85311 claims |
| AmgenEvenity (2 Syringes) | $525 | $35,56114 claims |
| AbbVieSynthroid | $68 | $15,537205 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $59 | $12,94715 claims |
| IBSA Pharma Inc.Tirosint | $18 | $6,48031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Austin
- Thomas BlevinsAustin$904K
- Lindsay HarrisonAustin$103K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.